Y-Intercept (HK)’s Cartesian Therapeutics RNAC Stock Holding History

Y-Intercept (HK)’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-451	Closed	-$18K	–	1224
2022 Q2	$18K	Buy	+451	New	+$13.4K	﹤0.01%	793

Other funds holding RNAC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Y-Intercept (HK)'s RNAC Position: Q3 2022 in Review

Y-Intercept (HK) sold out of Cartesian Therapeutics (RNAC) in Q3 2022, closing a stake of 451 shares — an estimated $18K sold.

Y-Intercept (HK) first reported a position in RNAC in Q2 2022 and held it in 1 quarter. The position peaked at $18K in Q2 2022. 96 funds tracked by Wall St. Rank hold RNAC as of Q3 2022.

Y-Intercept (HK) reported no remaining Cartesian Therapeutics position as of Q3 2022 after selling out during the quarter.
Y-Intercept (HK) sold 451 Cartesian Therapeutics shares in Q3 2022, an estimated $18K.
Y-Intercept (HK) first reported a position in Cartesian Therapeutics in Q2 2022 and held it in 1 quarter.
Y-Intercept (HK)'s Cartesian Therapeutics position peaked at $18K in Q2 2022.
96 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2022.

Based on Y-Intercept (HK)'s 13F filing for Q3 2022, filed 14 Feb 2023.